<DOC>
	<DOC>NCT00151333</DOC>
	<brief_summary>To determine the safety and tolerability of multiple ascending fixed oral doses of SRA-333 in subjects with mild to moderate Alzheimer's disease.</brief_summary>
	<brief_title>Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis of probable AD according to the NINCDSADRDA criteria. Men and postmenopausal or surgically sterile women aged from 50 to 85 inclusive. Able to give informed consent. Patient's caregiver must consent to participate in the study. Significant neurologic disease other than AD that may affect cognition. Current clinically significant systemic illness which is likely to deteriorate or affect the subject's safety during the study. Other exclusions apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>